44,051 Shares in Pfizer Inc. $PFE Acquired by Secured Retirement Advisors LLC

Secured Retirement Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the first quarter, Holdings Channel.com reports. The firm acquired 44,051 shares of the biopharmaceutical company’s stock, valued at approximately $1,237,000.

Several other institutional investors have also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Pfizer in the fourth quarter valued at $1,830,986,000. Morgan Stanley lifted its holdings in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Pfizer by 38.9% in the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Franklin Resources Inc. grew its holdings in Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after buying an additional 8,108,887 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Pfizer by 577.5% during the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after buying an additional 7,489,189 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $23.88 on Thursday. The stock has a market cap of $136.07 billion, a P/E ratio of 18.23 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $25.74 and its two-hundred day moving average price is $26.26. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. HSBC boosted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. CICC Research began coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer remains a possible beneficiary of growing investor interest in GLP-1 and obesity-treatment themes, with several recent pieces highlighting its weight-loss pipeline as a potentially underrated growth driver. Article Title
• Positive Sentiment: Commentary suggesting Pfizer may be undervalued has kept the stock on some investors’ watchlists, especially given its low valuation relative to its pipeline and dividend yield. Article Title
• Neutral Sentiment: Erste Group trimmed its FY2026 EPS estimate slightly to $2.95 from $2.96, a small change that adds to the cautious tone but is unlikely to materially alter the investment thesis on its own.
• Neutral Sentiment: Pfizer’s real-world COVID-19 vaccine study is nearing a data reveal, which could matter for sentiment, but the market impact is still uncertain until results are disclosed. Article Title
• Negative Sentiment: Recent coverage continues to emphasize Pfizer’s fading pandemic-era revenue stream, with Comirnaty and Paxlovid declines weighing on the company’s growth profile and investor sentiment. Article Title
• Negative Sentiment: Market coverage also noted the shares have been declining while the broader market improved, reinforcing the view that investors remain cautious on Pfizer near term. Article Title

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.